Exane Derivatives Pliant Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 234 shares of PLRX stock, worth $2,499. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234
Previous 5,290
95.58%
Holding current value
$2,499
Previous $37,000
97.3%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding PLRX
# of Institutions
170Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$63.8 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$53.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$51.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$37.7 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$34.1 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $520M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...